VX-702: Selective ATP-Competitive p38α MAPK Inhibitor for Inflammation Research

Executive Summary: VX-702 is a highly selective, ATP-competitive inhibitor of p38α mitogen-activated protein kinase (MAPK14), with an IC50 of 4–20 nM under standard kinase assay conditions (APExBIO, VX-702). It achieves dose-dependent inhibition of key pro-inflammatory cytokines, including IL-6, IL-1β, and TNFα, in LPS-stimulated ex vivo blood assays (Stadnicki et al., 2024). In vivo, VX-702 reduces joint erosion and inflammation in collagen-induced arthritis mouse models, rivaling methotrexate and prednisolone (Stadnicki et al., 2024). The compound exhibits favorable pharmacokinetics, with linear renal excretion and no significant interaction with organic ion transporters. VX-702 also preserves platelet mitochondrial function during storage, without inducing aggregation or calcium flux. The product is provided by APExBIO for research use only.

Biological Rationale

p38α MAPK (MAPK14) is a serine/threonine kinase central to the cellular response to pro-inflammatory cytokines and environmental stressors (Stadnicki et al., 2024). Aberrant activation of the p38 MAPK signaling pathway is implicated in autoimmune diseases, rheumatoid arthritis, and acute coronary syndromes. Inhibition of p38α MAPK disrupts downstream cytokine signaling, offering a strategy for modulating inflammation and tissue damage (Redefining Inflammation Research). VX-702 was developed to address the selectivity and off-target limitations of first-generation p38 inhibitors.

Mechanism of Action of VX-702

VX-702 acts as an ATP-competitive inhibitor, binding to the active site of p38α MAPK and stabilizing an inactive kinase conformation. This direct inhibition blocks the phosphorylation of downstream substrates required for cytokine production and stress signaling (Stadnicki et al., 2024). Recent structural studies reveal that VX-702 and similar inhibitors not only occlude the ATP binding site but also promote a conformational shift that increases accessibility of the activation loop phospho-threonine to phosphatases such as WIP1, facilitating kinase dephosphorylation and double-layered inhibition (Stadnicki et al., 2024). This dual mechanism enhances both potency and selectivity compared to less conformationally selective inhibitors (VX-702: Mechanistic Insights—this article extends the discussion to recent conformational biology findings).

Evidence & Benchmarks

• VX-702 inhibits p38α MAPK (MAPK14) activity with an IC50 of 4–20 nM in cell-free enzymatic assays (APExBIO datasheet, product page).
• In LPS-stimulated human blood, VX-702 causes dose-dependent suppression of IL-6, IL-1β, and TNFα production (ex vivo, 37°C, 5% CO₂, 4 h; Stadnicki et al., 2024).
• Mouse collagen-induced arthritis models show oral VX-702 (30 mg/kg/day) reduces joint erosion and inflammation comparable to methotrexate and prednisolone (Stadnicki et al., 2024).
• In rat perfused kidney models, VX-702 demonstrates linear renal excretion and reabsorption; not a substrate for organic anion/cation transporters (pH 7.4, 37°C; Stadnicki et al., 2024).
• Platelet storage studies indicate VX-702 preserves mitochondrial, metabolic, and functional parameters over 7 days at 22°C without inducing aggregation or Ca²⁺ mobilization (platelet-rich plasma, 22°C; Stadnicki et al., 2024).
• In myocardial ischemia-reperfusion injury models, VX-702 reduces infarct size by selective inhibition of p38 MAPK, with no inhibitory effect on ERK or JNK (mouse, 37°C, 30 min ischemia/2 h reperfusion; Stadnicki et al., 2024).

Applications, Limits & Misconceptions

VX-702 is used extensively in preclinical models of inflammation, autoimmune disease, and cardiovascular injury. Its chemical stability, high selectivity, and solubility in DMSO (>20.2 mg/mL) make it suitable for both in vitro and in vivo studies. VX-702 does not directly induce platelet aggregation or disrupt calcium homeostasis, supporting its use in platelet storage lesion research. Pharmacokinetic studies reveal minimal interaction with renal transporters, reducing risk of transporter-mediated clearance artifacts.

For more on optimizing cell-based workflows with VX-702, see Optimizing Cell Assays and Inflammation Research with VX-702; this article provides updated guidance on mechanistic best practices and advanced protocol integration.

Common Pitfalls or Misconceptions

• VX-702 is not a pan-MAPK inhibitor; it does not inhibit ERK1/2 or JNK under standard conditions (Stadnicki et al., 2024).
• It is not suitable for diagnostic or clinical use; intended for research applications only (APExBIO).
• Stock solutions are unstable at room temperature and should be stored at -20°C; repeated freeze-thaw cycles reduce potency (APExBIO datasheet).
• VX-702 is insoluble in water and requires DMSO or ethanol for preparation; improper solubilization leads to precipitation and assay variability.
• Direct effects on immune cell proliferation or apoptosis are not a primary mechanism; observed effects are mediated by p38α MAPK inhibition.

Workflow Integration & Parameters

VX-702 (SKU: A8687) from APExBIO is provided as a solid powder with a molecular weight of 404.33. For in vitro studies, reconstitute in DMSO at concentrations up to 20.2 mg/mL. For in vivo studies, prepare dosing solutions in ethanol or DMSO, diluted in vehicle as appropriate. Use within 2 weeks when stored at -20°C in aliquots to avoid degradation. Typical working concentrations for cell assays range from 10 nM to 1 μM, depending on target and cell type. Always verify solubility and assay compatibility prior to large-scale experiments. For detailed scenario-driven best practices, see VX-702, P38α MAPK Inhibitor: Scenario-Driven Best Practices; this resource complements the present article with validated workflows and troubleshooting advice.

Conclusion & Outlook

VX-702 represents a new generation of selective, ATP-competitive p38α MAP kinase inhibitors optimized for research in cytokine signaling, inflammation, and cardiovascular injury. Its dual-action mechanism—active site blockade and conformationally enhanced dephosphorylation—provides a refined tool for dissecting MAPK14-dependent pathways. As a research compound provided by APExBIO, VX-702 supports reliable, mechanistically informed discoveries in both basic and translational models. Ongoing structural and pharmacological research will further define its therapeutic and investigative potential. For continued updates on mechanistic advances, see VX-702 and the New Era of p38α MAPK Inhibition; this article expands on future research directions and translational prospects beyond the current dossier.